Principles for designing an optimal mRNA lipid nanoparticle vaccine
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Principles for designing an optimal mRNA lipid nanoparticle vaccine
Authors
Keywords
-
Journal
CURRENT OPINION IN BIOTECHNOLOGY
Volume 73, Issue -, Pages 329-336
Publisher
Elsevier BV
Online
2021-10-27
DOI
10.1016/j.copbio.2021.09.016
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles
- (2021) Uri Elia et al. ACS Nano
- Nanomaterial Delivery Systems for mRNA Vaccines
- (2021) Michael D. Buschmann et al. Vaccines
- BNT162b vaccines protect rhesus macaques from SARS-CoV-2
- (2021) Annette B. Vogel et al. NATURE
- Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype
- (2021) Steve Pascolo Viruses-Basel
- mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability
- (2021) Linde Schoenmaker et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- The dawn of mRNA vaccines: The COVID-19 case
- (2021) Rein Verbeke et al. JOURNAL OF CONTROLLED RELEASE
- What it will take to vaccinate the world against COVID-19
- (2021) Aisling Irwin NATURE
- Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines
- (2021) Kellie D. Nance et al. ACS Central Science
- Lipids and Lipid Derivatives for RNA Delivery
- (2021) Yuebao Zhang et al. CHEMICAL REVIEWS
- CureVac COVID vaccine let-down spotlights mRNA design challenges
- (2021) Elie Dolgin NATURE
- Lipid nanoparticles for mRNA delivery
- (2021) Xucheng Hou et al. Nature Reviews Materials
- Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2
- (2021) Javier T. Granados-Riveron et al. BIOMEDICINE & PHARMACOTHERAPY
- Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
- (2021) Peter G Kremsner et al. LANCET INFECTIOUS DISEASES
- SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
- (2020) Kizzmekia S. Corbett et al. NATURE
- Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection
- (2020) Edo Kon et al. Pharmaceutics
- Long-term storage of lipid-like nanoparticles for mRNA delivery
- (2020) Pengxuan Zhao et al. Bioactive Materials
- mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
- (2020) Shuqin Xu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Addressing the Cold Reality of mRNA Vaccine Stability
- (2020) Daan J.A. Crommelin et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo
- (2019) Yusuke Sato et al. JOURNAL OF CONTROLLED RELEASE
- Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
- (2019) Kimberly J. Hassett et al. Molecular Therapy-Nucleic Acids
- A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates
- (2018) Staci Sabnis et al. MOLECULAR THERAPY
- Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles
- (2018) Marianna Yanez Arteta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mRNA as novel technology for passive immunotherapy
- (2018) Thomas Schlake et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening
- (2018) Alexandra G. Orlandini von Niessen et al. MOLECULAR THERAPY
- Short poly(A) tails are a conserved feature of highly expressed genes
- (2017) Sarah Azoubel Lima et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Short poly(A) tails are a conserved feature of highly expressed genes
- (2017) Sarah Azoubel Lima et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses
- (2016) Ans De Beuckelaer et al. MOLECULAR THERAPY
- N 1 -methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice
- (2015) Oliwia Andries et al. JOURNAL OF CONTROLLED RELEASE
- Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals
- (2015) Andreas Thess et al. MOLECULAR THERAPY
- mRNA transcript therapy
- (2014) Drew Weissman Expert Review of Vaccines
- mRNA-based therapeutics — developing a new class of drugs
- (2014) Ugur Sahin et al. NATURE REVIEWS DRUG DISCOVERY
- Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
- (2013) Martin A Maier et al. MOLECULAR THERAPY
- Type I IFN Counteracts the Induction of Antigen-Specific Immune Responses by Lipid-Based Delivery of mRNA Vaccines
- (2012) Charlotte Pollard et al. MOLECULAR THERAPY
- Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
- (2010) Bart R. Anderson et al. NUCLEIC ACIDS RESEARCH
- Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
- (2008) Katalin Karikó et al. MOLECULAR THERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now